Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at biomarkers in cell samples from patients with acute myeloid leukemia.
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: protein expression analysis
Other: fluorescence activated cell sorting
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Critical Role of MicroRNA-34a and MicroRNA-194 in Acute Myeloid Leukemia With CEBPA Mutations|
- Significance of regulation of microRNA-34a and microRNA-194 by C/EBPα during granulopoiesis
- Relationship between overexpression of microRNA-34a and microRNA-194 in myeloid progenitors with C/EBPα mutations and granulocytic differentiation
- Downregulation of E2F3 by microRNA-34a and microRNA-194 during granulopoiesis
- Role of microRNA-34a and microRNA-194 in myeloid cell proliferation
Biospecimen Retention: Samples With DNA
|Study Start Date:||January 2010|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
- To determine the significance of regulation of microRNA-34a and microRNA-194 by C/EBPα during granulopoiesis in patients with acute myeloid leukemia with CEBPA mutations.
- To determine whether overexpression of micro RNA-34a and microRNA-194 in myeloid progenitors with C/EBPα mutations leads to granulocytic differentiation.
- To examine how microRNA-34a and microRNA-194 downregulate E2F3 during granulopoiesis.
- To determine the role of microRNA-34a and microRNA-194 in myeloid cell proliferation.
OUTLINE: Cryopreserved cell samples are collected for laboratory analysis, including mutation analysis, gene expression analysis, RNA analysis, and fluorescence-activated cell sorting (FACS) analysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01057199
|Principal Investigator:||Soheil Meshinchi, MD||Fred Hutchinson Cancer Research Center|